Abstract：
Parkinson\'s disease (PD) is the second most common neurodegenerative disease and is growing in prevalence and disability. The standard treatment for PD is oral levo-dopa (LD) with carbidopa (CD). As PD progresses, despite higher doses of LD/CD, plasma levels of LD fluctuate, and may be associated with motor fluctuations and dyskinesia.
The development of two new subcutaneous preparations of LD/CD (ND0612 and ABBV-951) for the treatment of motor fluctuations in PD is described in detail. Both reduce motor fluctuations and dyskinesia with minor infusion site adverse events. A third subcutaneous preparation, DIZ102, is in early-stage development.
The premise for using continuous release LD in advanced PD is that steady state levels of LD will prevent motor fluctuations/dyskinesia, but this is not the whole story, and will limit the benefits of subcutaneous continuous release LD. With its present pump system ND0612 cannot be used as monotherapy, whereas ABBV-951 can be. Having to combine with oral LD/CD will complicate the use of ND0612. Both ND0612 and ABBV-951 only cause modest reductions in OFF time. It is not clear whether these subcutaneous preparations will have more benefits than the intestinal gel, which also reduces OFF time and dyskinesia.
The development of two new subcutaneous preparations of LD/CD (ND0612 and ABBV-951) for the treatment of motor fluctuations in PD is described in detail. Both reduce motor fluctuations and dyskinesia with minor infusion site adverse events. A third subcutaneous preparation, DIZ102, is in early-stage development.
The premise for using continuous release LD in advanced PD is that steady state levels of LD will prevent motor fluctuations/dyskinesia, but this is not the whole story, and will limit the benefits of subcutaneous continuous release LD. With its present pump system ND0612 cannot be used as monotherapy, whereas ABBV-951 can be. Having to combine with oral LD/CD will complicate the use of ND0612. Both ND0612 and ABBV-951 only cause modest reductions in OFF time. It is not clear whether these subcutaneous preparations will have more benefits than the intestinal gel, which also reduces OFF time and dyskinesia.
摘要：
■帕金森病（PD）是第二常见的神经退行性疾病，患病率和残疾率都在上升。PD的标准治疗是口服左旋多巴(LD)和卡比多巴(CD)。随着PD的进展,尽管LD/CD的剂量较高，血浆LD水平波动，并可能与运动波动和运动障碍有关。
■详细描述了两种用于治疗PD中运动波动的LD/CD（ND0612和ABBV-951）的新皮下制剂的开发。两者均可减少运动波动和运动障碍，并伴有轻微的输注部位不良事件。第三种皮下准备，DIZ102处于早期开发阶段。
■在高级PD中使用连续释放LD的前提是，LD的稳态水平将防止运动波动/运动障碍，但这不是全部,并将限制皮下连续释放LD的益处。其现有的泵系统ND0612不能用作单一疗法，而ABBV-951可以。必须与口服LD/CD组合将使ND0612的使用复杂化。ND0612和ABBV-951两者仅引起关闭时间的适度减少。目前还不清楚这些皮下制剂是否会比肠道凝胶有更多的好处，这也减少了OFF时间和运动障碍。
■详细描述了两种用于治疗PD中运动波动的LD/CD（ND0612和ABBV-951）的新皮下制剂的开发。两者均可减少运动波动和运动障碍，并伴有轻微的输注部位不良事件。第三种皮下准备，DIZ102处于早期开发阶段。
■在高级PD中使用连续释放LD的前提是，LD的稳态水平将防止运动波动/运动障碍，但这不是全部,并将限制皮下连续释放LD的益处。其现有的泵系统ND0612不能用作单一疗法，而ABBV-951可以。必须与口服LD/CD组合将使ND0612的使用复杂化。ND0612和ABBV-951两者仅引起关闭时间的适度减少。目前还不清楚这些皮下制剂是否会比肠道凝胶有更多的好处，这也减少了OFF时间和运动障碍。
